The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2018 | Evolving management of relapsed CLL: UK CLL Forum analysis of ibrutinib at first relapse
There are an array of new strategies evolving to manage relapsed chronic lymphocytic leukemia (CLL). In this interview, George Follows, MA, BM, BCh, PhD, FRCP, FRCPath, from Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, discusses the exciting UK CLL Forum analysis of patients treated with ibrutinib at first relapse. Dr Follows highlights the fascinating results identified between patients with early and late relapse. This interview was recorded at the British society for Hematology (BSH) 2018 Annual Scientific Meeting, held in Liverpool, UK.
